An in vitro model comprised of primary cul tures of brain microvessel endothelial cells was used to investigate angiotensin II (Ang II) effects on blood-brain barrier fluid-phase endocytosis. The effects of Ang II, saralasin, sarathrin, bradykinin (BK), and phorbol myristate acetate (PMA) on brain microvessel endothelial cell fluid-phase endocytosis were determined using the fluorescent marker, Lucifer yellow. Nanomolar concen trations of saralasin (a partial Ang II agonist) stimulated brain microvessel endothelial cell endocytosis by 30% whereas Ang II treatment enhanced Lucifer yellow up take by 20%. Sarathrin (an Ang II antagonist) had no effect on Lucifer yellow uptake. Nanomolar concentra tions of BK and PMA also stimulated Lucifer yellow up take by the brain microvessel endothelial cell by 40 and 95%, respectively. Stimulatory effects of Ang II and sa-Pinocytosis is a cellular mechanism for acquiring metabolic needs and bulk movement of macromol ecules and fluid. Normally, pinocytosis is attenu ated within endothelia that comprise the blood brain barrier (BBB) as demonstrated by the paucity of intracellular vesicles at the ultrastructural level in vivo (Reese and Karnovsky, 1967). Fluid-phase en docytosis within primary cultures of brain mi crovessel endothelial cell monolayers, an in vitro
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BBB model, has also been shown to be significantly reduced relative to other cell types and differs in accumulation kinetics compared to endothelia from other tissues (Guillot et aI. , 1990) . Under patho physiological conditions, including hypertension, pinocytic activity of the BBB is a potentially impor tant mechanism in the development of vasogenic edema (Wahl et aI. , 1988) .
Multiple lines of evidence support the existence of a vascular wall renin-angiotensin system inde pendent of the circulating system. This evidence is based on several studies that have demonstrated biochemically the presence of renin-angiotensin components in major organ systems (Dzau, 1984 (Dzau, ,1986 Frohlich et aI. , 1989) . Thus, it has been proposed that angiotensin release by vascular cells of major organ systems may have an important au tocrine or paracrine influence on local blood vessel function including the development of hypertension and vasospasm, independent of the circulating sys-tern (Dzau, 1984 (Dzau, ,1986 Frohlich et aI., 1989) . Sev eral studies have provided evidence for a local re nin-angiotensin system within the endothelium forming the BBB. This evidence includes the exis tence of specific angiotensin binding sites (Speth and Harik, 1985; Grammas et aI., 1989) , angioten sin-induced changes in permeability (Grubb and Raichle, 1981; Oztas and Sandalci, 1984) , and met abolic pathways for the synthesis and degradation of angiotensin (Orlowski and Wilk, 1978) .
One of several abnormalities of the cerebrovas cular walls is an increased permeability, observed following various insults to the brain including acute hypertension. Angiotensin-induced changes in BBB permeability have been described in vivo (Grubb and Raichle, 1981; Oztas and Sandalci, 1984) . However, the mechanism of angiotensin induced permeability changes at the BBB is not clear. At least one report has shown that angioten sin-induced acute hypertension enhances pinocytic activity in cerebral vessels (Johansson, 1981) . The aim of this report was to use primary cultures of brain microvessel endothelial cells as an in vitro model to characterize the role of the renin angiotensin system in modulating BBB functions. Specifically, fluid-phase endocytosis was studied as a possible mechanism in permeability changes in the BBB under pathophysiological conditions such as hypertension.
METHODS

Cell culture
Bovine brain microvessel endothelial cells were iso lated from gray matter of cerebral cortices by enzymatic dispersal and subsequent centrifugation, and seeded into primary culture as detailed by Borchardt (1986a, 1987) . These cells have been extensively charac terized ultrastructurally, biochemically, and immunohis tochemically as an appropriate in vitro model of the BBB Borchardt, 1986a,b, 1987; Baranczyk-Kuzma et aI., 1986; Guillot et aI., 1990) . The purity of the cul tures, as detailed elsewhere (Guillot et aI., 1990) , indi cates that at least 99.5% of the cells in a monolayer im munostain positively for factor VIII antigen, a marker for cells of endothelial origin. Isolated brain microvessel en dothelial cells were seeded at a density of 50,000 cells!cm2 into 24-well plates (Corning, Corning, NY, U.S.A.), pre treated with rat tail collagen and fibronectin (Sigma Chemical Co., St. Louis, MO, U.S.A.), in a culture me dium consisting of 45% minimum essential medium, 45% F-12 Ham's nutrient mix (Dutchland-Hazelton, Lenexa, KS, U.S.A.), 10% plasma-derived equine serum (Hy Clone Laboratories, Logan, UT, U.S.A.), 100 J..L g!ml hep arin, 50 J..L g!ml of gentamicin, and 2.5 J..L g!ml of amphoteri cin B (Sigma Chemical Co.). Cells were refed every 2 days after seeding Borchardt, 1986a, 1987) . After formation of a confluent monolayer (10-14 days), experiments were performed.
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The protocol of Swanson et al. (1985) , as modified by for endothelial cells, was used to char acterize the effects of angiotensin II (Ang II), saralasin, sarathrin, bradykinin (BK) (Peninsula Laboratories, Bel mont, CA, U.S.A.), and phorbol myristate acetate [(PMA) Sigma Chemical Co.] on fluid-phase endocytosis of the fluorescent probe Lucifer yellow CH (Molecular Probes, Eugene, OR, U.S.A.). Briefly, Lucifer yellow was dissolved in culture medium to a final concentration of 0.5 mg!ml. Aliquots of 0.45 ml of this stock solution were added to each well as a 24-well culture plate for 30 min in the presence of 0.5 to 500 nM concentrations of Ang II (Asp--Arg-Val-Tyr-Ile-His-Pro-Phe), saralasin (Sar-Arg-Val-Tyr-Ile-His-Pro-Ala; a partial Ang II ag onist), sarathrin (Sar-Arg-Val-Tyr-Ile-His-Pro-Thr; an Ang II antagonist), BK (Arg-Pro-Pro-Gly Phe-Ser-Pro-Phe-Arg), or 10 to 100 ng!ml of PMA. Pep tides and PMA were dissolved in phosphate-buffered sa line (PBS), pH 7.4, and added in 10 to 50 J..L I aliquots to the Lucifer yellow:culture medium mixture to give the final volume of 0.45 ml added to 24-well plate wells. Corre sponding control wells received a Lucifer yellow:culture medium mixture containing an equivalent aliquot of PBS alone. In some experiments, brain microvessel endothe lial cell monolayers were pretreated with 100 ng/ml of indomethacin (added into the culture medium) (Sigma Chemical Co.) for 24 h prior to a Lucifer yellow uptake study. Brain microvessel endothelial cell monolayers were in other experiments pretreated with trifluoperazine or chloroquine (Sigma Chemical Co.) for 60 or 90 min, respectively, prior to performing a Lucifer yellow uptake study.
For "reversibility" experiments, cells were pretreated with different concentrations of saralasin for 30 min at 3rC. The mono layers were rinsed and incubated in sar alasin-free buffer for 30 min at 37°C. Cells were incubated with 0.5 mg!ml of Lucifer yellow in culture medium for 30 min at 3rC in the presence of indicated concentrations of peptides.
Following the 30 min incubation with the Lucifer yel low:culture medium mixtures at 3rC in a CO2 incubator, the 24-well plates were drained and quickly rinsed three times with 4°C PBS containing 1 mg/ml bovine serum albumin (Sigma Chemical Co.). Monolayers in each well were solubilized by the addition of 0.5 ml of PBS con taining 0.05% (vol/vol) Triton X-l00 (Sigma Chemical Co.) in an acrylic cuvet (Fisher Scientific, St. Louis, MO, U.S.A.). Fluorescence was measured with an SLM AMINCO Fluorometer, Model 4800 (Urbana, IL, U.S.A.), with the sample excited at 430 nm (8 nm slit) and emission observed at 540 nm (8 nm slit).
Cell lysate samples were also taken for determination of cell protein by a modified Lowry assay using 1% (wt! vol) sodium dodecyl sulfate (Markwell et aI., 1981) .
Viability of the brain microvessel endothelial cell monolayers has been shown to be unaltered by the con ditions of the assays and the concentrations of substances used above by both trypan blue exclusion here and DNA synthesis in related studies .
Statistics
Percent of control was calculated as Lucifer yellow up take by treated monolayers divided by Lucifer yellow uptake in control monolayers times 100%. For statistical comparisons, raw data for treated monolayers were tested for statistical difference from raw data for control monolayers by analysis of variance (ANOV A) and the Neuman-Keuls multiple comparisons test at the 0.05 level of significance (Rosner, 1982) .
RESULTS
The uptake of Lucifer yellow by brain microves sel endothelial cells in control monolayers was de termined to be 265 ± 24 ng/mg protein as previously detailed . Accumulation of Lu cifer yellow by brain microvessel endothelial cells was stimulated on exposure to oM concentrations of Ang II agonists. Whereas Ang II enhanced brain microvessel endothelial cell fluid-phase endocytosis by more than 20% at a concentration of SO oM (Fig.  1A) , 3 oM saralasin maximally stimulated Lucifer yellow uptake by about 30% (Fig. 1B) . Sarathrin, an Ang II antagonist, had no effect on Lucifer yellow uptake (Fig. 1C) .
On 24-h pretreatment of the brain microvessel en dothelial cell mono layers with 100 ng/ml indometha cin, both Ang II's and saralasin's stimulatory effect on Lucifer yellow uptake was inhibited (Fig. 2) . In domethacin alone did not statistically alter brain mi crovessel endothelial cell uptake of Lucifer yellow compared to controls (data not shown). Sarathrin could block Ang II's stimulatory effect on Lucifer yellow uptake by brain microvessel endothelial cells; however, saralasin did not antagonize Ang II-stimulated brain microvessel endothelial cell up take of Lucifer yellow ( Fig. 3A and B ). Indometha cin pretreatment did block the combined Ang II and saralasin-mediated effects on brain microvessel endothelial cell fluid-phase endocytosis (Fig. 3C ).
The influence of angiotensin peptides appeared to last for a relatively short period of time. The stim ulatory effects of saralasin on Lucifer yellow uptake by brain microvessel endothelial cells were re versed when the monolayers, after having been ex posed to saralasin, were incubated in saralasin-free buffer for 30 min, and then assayed for Lucifer yel low incorporation (Fig. 4 ). Although not statisti cally different from controls, Lucifer yellow uptake by brain microvessel endothelial cells in these "reversibility" experiments tended to be attenu ated.
Bradykinin maximally stimulated a 40% increase in Lucifer yellow uptake by brain microvessel en dothelial cell monolayers at 100 oM (Fig. SA) . In contrast to angiotensin peptides, BK's effects on fluid-phase endocytosis were not altered by indo methacin pretreatment (Fig. SB) . The maximal stimulation of Lucifer yellow uptake was 90% for the metabolically stable PMA at a concentration of 100 ng/ml (Fig. 6A ). Like BK, the stimulatory effect of brain microvessel endothelial cell uptake of Lu cifer yellow due to PMA could not be substantially inhibited by indomethacin pretreatment (Fig. 6B) .
In other experiments, PMA effects on fluid-phase endocytosis were completely inhibited by pretreat ment with 2S ILM trifluoperazine (Fig. 7) . In con trast, trifluoperazine did not block the stimulatory effect of 3 oM saralasin on brain microvessel endo thelial cell uptake of Lucifer yellow. Trifluopera- Each bar represents the mean of six samples ± SO. Raw data for treated mono layers were not statistically different from raw data for control monolayers by ANOVA and the New man-Keuls multiple comparisons test at the 0.05 level of sig nificance at any concentration tested.
zine alone did not alter brain microvessel endothe lial cell uptake of Lucifer yellow (data not shown). Finally, chloroquine, a weak base that interacts with endosomal compartments, completely abol ished the saralasin-induced effect on Lucifer yellow uptake. Chloroquine pretreatment also significantly reduced the PMA-mediated effect on fluid phase endocytosis by brain microvessel endothelial cells (Fig. 7) .
DISCUSSION
We have used a well characterized in vitro model (Audus and Borchardt, 1986a ,1986b Baranc zyk-Kuzma et al. , 1986; to ex amine the role of angiotensin peptide regulation of BBB fluid-phase endocytosis. Our results indicated that brain microvessel endothelial cell fluid-phase endocytosis was transiently stimulated on exposure to oM concentrations of Ang II agonists. Although -Raw data for treated monolayers were statistically different from raw data for control monolayers by ANOVA and the Newman-Keuls multiple comparisons test at the 0.05 level of significance.
saralasin is considered a partial agonist, it appeared to enhance Lucifer yellow uptake to a greater de gree and at a lower concentration than Ang II. We suggest that saralasin' s more pronounced effects upon brain microvessel endothelial cell fluid-phase endocytosis may reside in its much higher stability and higher affinity for the Ang II receptor (Douglas, 1985) . The magnitude of these changes was consis tent with those reported for permeability changes observed in peripheral vascular endothelial cells on exposure to catecholamines, serotonin, or hista mine (Bottaro et a!., 1986). These findings were also in agreement with animal studies in which nanomo lar concentrations of saralasin produced increases in BBB permeability (Grubb and Raichle, 1981; Oz tas and Sandaki, 1984) . Gimbrone and Alexander (1975) have shown that Ang II stimulates production of vasoactive pros taglandins (PGE-like material) by cultured endothe lium. Prostaglandin production could be completely inhibited by pretreatments of 1 00 ng/ml of indo methacin (Gimbrone and Alexander, 1975) . Indo methacin-induced inhibition of angiotensin stimulated Lucifer yellow uptake suggests that prostaglandins may modulate brain microvessel en dothelial cell fluid-phase endocytosis. In this model, it appears unrealistic to link directly the vas oconstrictor response mediated by Ang II with an increase in Lucifer yellow uptake (although acute hypertension enhances pinocytosis in cerebral blood vessels). It would be more reasonable to sug gest that the subsequent dilatory action due to pros taglandins in response to Ang II pressor action (Su sic et a!., 1981) might be related to fluid-phase en docytosis since indomethacin inhibited instead of augmenting the Ang II-mediated increase in Lucifer yellow uptake. Pharmacological modification of the BBB during hypertension seems to support the hy- pothesis that vesicular transport is of importance (Hansson and Johansson, 1979) . A precise physio logical role for fluid-phase endocytosis subsequent to Ang II exposure is not clear at this time. How ever, Gryglewski et a!. (1988) have proposed that the release of endothelium-derived relaxing factor (EDRF) and prostacyclins following exposure to BK or Ang II alters various vascular cell surface functions as part of a common defense mechanism. Specific Ang II binding sites have been previ ously characterized on brain microvessels obtained by bulk isolation from the cerebral cortex and cer ebellum of canine (Speth and Harik, 1985) and rat brain (Grammas et a!., 1989) . Ang II agonists, but not the antagonist sarathrin, a pure antagonist, were shown to stimulate Lucifer yellow uptake by brain microvessel endothelial cells here. We have also determined that sarathrin blocks Ang II stimulation of Lucifer yellow uptake by brain microvessel en dothelial cells. These findings suggest possible trig- gering of fluid-phase endocytosis by a specific Ang II binding site. Additional work in our laboratories has confirmed the existence of a single population of Ang II binding sites on primary cultures of brain microvessel endothelial cell monolayers. The spe cific Ang II binding of a high-affinity site was satu rable and competitive with Ang II analogs . In addition, the Kd for the high affinity Ang II binding site was 3.0 nM, which agrees well with concentrations of angiotensin II observed to stimulate Lucifer yellow uptake in this study. Bradykinin and PMA, positive controls in this study, both stimulated Lucifer yellow uptake by the cells, consistent with other reports (Swanson et aI., 1985; Raymond et aI., 1986) . Past studies in our laboratories have demonstrated that other sub stances such as vincristine and aluminum (negative controls) can attenuate Lucifer yellow uptake by brain microvessel endothelial cells (Audus et aI., Percent of control was calculated as Lucifer yellow uptake by treated monolayers divided by Lucifer yellow uptake in con trol monolayers times 100%. Each bar represents the mean of six samples :t SD. 'Raw data for treated monolayers were statistically different from raw data for control monolayers by ANOVA and the Newman-Keuls multiple comparisons test at the 0.05 level of significance.
1988). Raymond et al. (1986) have suggested that an increase primarily in pinocytic activity at the BBB explained the increase in BBB permeability follow ing BK exposure and that increases in intercellular junction permeability were probably not involved.
Our results appear to be consistent with that hy pothesis. The lack of an apparent prostaglandin mediation for BK's effects on brain microvessel en dothelial cell uptake of Lucifer yellow also ob served here was not unusual. Furchgott (1984) has cited evidence indicating that mediation of BK ef fects on endothelium by prostaglandins is species and vessels dependent. In fact, in humans, pros taglandins are not released following BK stimula tion of endothelium. Furthermore, it has been shown that in addition to prostaglandins, BK ac tions may be mediated by other substances such as EDRF and lipoxygenases (Raymond et aI., 1986) . The effects of PMA on Lucifer yellow uptake by brain microvessel endothelial cells were also inves tigated in our report since it has been shown that PMA induces endocytosis in several cell types. The extent of PMA-induced fluid-phase endocytosis ac tivation observed with brain microvessel endotheli al cell monolayers was of similar magnitude to re ported PMA-induced changes in endocytosis ob served by Swanson et al. (1985) with macrophages. Like BK, PMA effects on brain microvessel endo thelial cell fluid-phase endocytosis were not sensi tive to indomethacin.
In other experiments, Lucifer yellow uptake by brain microvessel endothelial cells in the presence of trifluoperazine or chloroquine, concomitantly with either saralasin or PMA, was determined. Tri fluoperazine inhibits both calmodulin-dependent and calcium-activated phospholipid-dependent ki nases including protein kinase C. This inhibition may enable trifluoperazine to stabilize cell mem branes in culture and reduce phagocytosis. Triflu operazine reduces BBB disruption in acute hyper tension (Johansson, 1981) ; suppression of pinocyto sis was suggested as a possible mechanism (Raymond et aI., 1986) . Recent evidence shows that protein kinase C is a prime target for actions of the phorbol esters (Nishizuka, 1984) . Trifluoperazine (TFP) abolished PMA-induced increases in Lucifer yellow uptake by brain microvessel endothelial cell monolayers, suggesting the essential link between PMA and protein kinase C (PKC) activation in our studies. On the other hand, 3 oM saralasin effects on Lucifer yellow uptake were not altered by TFP pretreatment. Ang II-induced transmembrane sig nals, in contrast to PMA, do not necessarily involve PKC activation. Resink et aI. (1989) , for instance, recently showed that Ang II-mediated responsive ness of vascular smooth muscle cells is unlikely to involve alterations in PKC in hypertension. Ac cordingly, these results suggest that brain microves sel endothelial cell fluid-phase endocytosis may be modulated through different biochemical pathways depending on the stimulant.
Translocation of Ang II to the cell interior has been described in several types of cultured cells (Crozat et aI., 1986; Griendling et aI., 1987) , includ ing brain microvessel endothelial cells . Ullian and Linas (1989) showed that Ang II exposure resulted in a loss of surface Ang II receptors (65% of the ligand was internalized by 20 min at 21°C) attributable to internalization of the receptor. In addition, they were able to show that incubation of Ang II with the endosomal inhibitor chloroquine (0.2 mM) resulted in a 70% greater loss of surface binding than after incubation with Ang II alone. Chloroquine is known to inhibit receptor re insertion within the plasma membrane by blocking endosomal trafficking (Tietze et aI., 1980; Pietra et aI., 1988) . Similarly, when saralasin and chloro quine were incubated together in our studies, the saralasin-induced effect on fluid-phase endocytosis in brain microvessel endothelial cells was likely re duced or inhibited because of a significant loss of binding sites. In other words, saralasin would be deprived of a significant number of binding sites and would not be able to stimulate Lucifer yellow up take by the brain microvessel endothelial cells.
In summary, we have shown that Ang II agonists stimulate fluid-phase uptake of Lucifer yellow and that prostaglandins may be responsible for these ef-fects. In contrast, BK and PMA can stimulate Lu cifer yellow uptake in a manner that appeared to be prostaglandin independent, suggesting that other biochemical pathways may also participate in regu lating brain microvessel endothelial cell fluid-phase endocytosis. These findings suggest that the in vitro model will provide a useful tool to investigate the biochemistry of vasoactive peptide regulation of BBB permeability through endocytic activity.
